Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

FLAIR

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD
Shobha Swaminathan, MD
Released: October 12, 2021

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Joseph J. Eron, Jr., MD

Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV Healthcare and funds for research support from Gilead Sciences, Janssen, and ViiV Healthcare.
Princy N. Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief,
Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP, has disclosed that she has received consulting fees from Amgen, Gilead Sciences, GlaxoSmithKline, Merck, and Theratechnologies; has received funds for research support from Amgen, Gilead Sciences, GlaxoSmithKline, and Merck; and has ownership interest in Gilead Sciences, Johnson & Johnson, Merck, and Pfizer.

Faculty

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Gilead Sciences and funds for research support from Gilead Sciences, Merck, and ViiV Healthcare.
Shobha Swaminathan, MD

Associate Professor
Division of Infectious Diseases
Department of Medicine
Rutgers New Jersey Medical School
Newark, New Jersey

Shobha Swaminathan, MD, has disclosed that she has received consulting fees from Gilead Sciences and ViiV Healthcare and funds for research support from Gilead Sciences.

Staff

Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Sarah Anderson, PharmD
Scientific Director
Sarah L. Anderson, PharmD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Jennifer Swanson, PharmD

Editorial Contributor

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who provide care for patients with HIV infection.

Goal

The goal of this activity is to improve learners’ competence in providing optimal care for patients with HIV through the appropriate use of contemporary ARV regimens.

Program Medium

This program has been made available online.

Related Content

Dr Milosz Parczewski and Clinical Care Options (CCO): Update from EACS 2021 on the HIV care continuum in Eastern Europe

Milosz Parczewski, MD, PhD Released: December 3, 2021

Expert recap of new data on rapid ART with BIC/FTC/TAF from EACS 2021, from Dr Monica Gandhi at Ward 86 and Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 1, 2021

Commentary from Dr Juan Luis Mosqueda Gomez on the latest findings from the IMEA 055 FAST study presented at EACS 2021 and how test-and-treat strategies could improve patient care and virologic suppression in Mexico, from Clinical Care Options (CCO)

Juan Luis Mosqueda Gomez, MD, MSc Released: December 1, 2021

Commentary from Dr Yan Zhao on the latest findings from EACS 2021 highlighting the unique challenges of older people living with HIV, from Clinical Care Options (CCO)

person default Yan Zhao, MD Released: November 30, 2021

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue